Neurocrine Biosciences, Inc.
NBIX
Clasificación en acciones
#1511
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Precio por acción
$141.77
Capitalización bursátil
$14.41B
Cambio (1 día)
3.49%
Cambio (1 año)
0.31%
País
US
Comercio Neurocrine Biosciences, Inc. (NBIX)
Categoría
Healthcare
Ratio P/E de Neurocrine Biosciences, Inc. (NBIX)
Ratio P/E al October 2026 TTM: 19.28
Según los últimos informes financieros y el precio de las acciones de Neurocrine Biosciences, Inc., el P/E actual (TTM) de la empresa es 19.28. Al final de 2023, la empresa tenía un P/E de 51.55.
Historial del ratio P/E de Neurocrine Biosciences, Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 19.28 | -51.99% |
| 2024 | 40.15 | -22.11% |
| 2023 | 51.55 | -30.39% |
| 2022 | 74.06 | -17.64% |
| 2021 | 89.92 | 310.43% |
| 2020 | 21.91 | -91.77% |
| 2019 | 266.19 | -17.51% |
| 2018 | 322.70 | -773.76% |
| 2017 | -47.90 | 101.73% |
| 2016 | -23.74 | -55.83% |
| 2015 | -53.75 | 95.32% |
| 2014 | -27.52 | 103.30% |
| 2013 | -13.54 | -113.86% |
| 2012 | 97.68 | 682.49% |
| 2011 | 12.48 | -124.65% |
| 2010 | -50.65 | 2,328.12% |
| 2009 | -2.09 | 50.22% |
| 2008 | -1.39 | 66.81% |
| 2007 | -0.83 | -77.30% |
| 2006 | -3.67 | -96.47% |
| 2005 | -103.92 | 166.53% |
| 2004 | -38.99 | -33.19% |
| 2003 | -58.36 | 296.31% |
| 2002 | -14.73 | -59.30% |
| 2001 | -36.18 | 42.23% |
| 2000 | -25.44 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | 49.30% |
US
|
|
| -28.36 | -247.10% |
US
|
|
| -24.57 | -227.43% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 57.33% |
NL
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.